Notes And Other Explanatory Information [Abstract]
| Concept |
2022-01-01 to 2022-12-31 |
|---|---|
| Notes and other explanatory information [abstract] | |
| Disclosure of accounting judgements and estimates [text block] |
3
|
| Disclosure of auditors' remuneration [text block] |
Note 26:
|
| Disclosure of basis of consolidation [text block] |
3
|
| Disclosure of borrowings [text block] |
3
|
| Disclosure of commitments [text block] |
Note 22:
|
| Disclosure of credit risk [text block] |
|
| Disclosure of derivative financial instruments [text block] |
3
|
| Disclosure of earnings per share [text block] |
Note 24:
|
| Disclosure of events after reporting period [text block] |
Note 27:
|
| Disclosure of fair value measurement [text block] |
3
|
| Disclosure of finance income (cost) [text block] |
Note 20:
|
| Disclosure of financial instruments at fair value through profit or loss [text block] |
Note 15:
|
| Disclosure of financial risk management [text block] |
Note 25:
|
| Disclosure of first-time adoption [text block] |
|
| Disclosure of general and administrative expense [text block] |
18
|
| Disclosure of general information about financial statements [text block] |
Note 1:
|
| Disclosure of going concern [text block] |
The Group’s future operations are highly dependent on a combination of factors, including: (i) the success of its research and development; (ii) regulatory approval and market acceptance of the Group’s proposed future products; (iii) the timely and successful completion of additional financing; and (iv) the development of competitive therapies by other biotechnology and pharmaceutical companies.
|
| Disclosure of impairment of assets [text block] |
4
|
| Disclosure of income tax [text block] |
3
|
| Disclosure of information about key management personnel [text block] |
Key management personnel compensation
|
| Disclosure of leases [text block] |
3
|
| Disclosure of liquidity risk [text block] |
|
| Disclosure of market risk [text block] |
|
| Disclosure of other current assets [text block] |
8
|
| Disclosure of other non-current assets [text block] |
Note 7:
|
| Disclosure of other non-current liabilities [text block] |
Note 13:
|
| Disclosure of other operating expense [text block] |
Note 18:
|
| Disclosure of other operating income [text block] |
Note 17:
|
| Disclosure of property, plant and equipment [text block] |
Note 5:
|
| Disclosure of provisions [text block] |
3
|
| Disclosure of related party [text block] |
19
|
| Disclosure of research and development expense [text block] |
18
|
| Disclosure of revenue [text block] |
3
|
| Disclosure of share capital, reserves and other equity interest [text block] |
4
|
| Disclosure of share-based payment arrangements [text block] |
3
|
| Disclosure of trade and other payables [text block] |
Note 14:
|
| Disclosure of trade and other receivables [text block] |
Note 8:
|